Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03334487
Title Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie

lung small cell carcinoma


Dexamethasone + Rovalpituzumab Tesirine

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.